Research progress of oral anticoagulants in patients with liver diseases / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 873-876, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-810264
ABSTRACT
Patients with liver disease are at an increased risk of both embolism and bleeding. The optimal anticoagulation strategy remains unclear when associated with venous thromboembolic disease. Moreover, currently approved oral anticoagulant drugs undergo metabolism and elimination in the liver with varying degrees of hepatic dysfunction. Thus, impaired liver function may lead to increased risk of bleeding, making anticoagulant therapy more intricate. This article summarizes the risk of bleeding and thrombosis in patients with liver disease, and the clinical research progress of oral anticoagulants in patients with liver disease to facilitate evidence for choosing oral anticoagulants therapy when required.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Hepatology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS